New Ask Claude or ChatGPT about any stock, using Bullpen. Bullpen in Claude or ChatGPT. 7 days free
Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Friday, November 13, 2026

Back to the front page

From X

@calvinblissett

Calvin Blissett on X

Yes and no lol, valuation and dividend yield are attractive currently (I added a few days ago ~$88), macro continues to trend in the right direction, I do hate $PDD just entered Kazakhstan, BUT what I surface level read is they can coexist well and $KSPI has a different approach than them from someone who I think is smart, pretty sure was @Benceno88 if you may elaborate friend. Also $KSPI management team will continue to find ways to pull rabbits out of the hat and grow within KZ, the most recent grocery vertical being an example
@StableBread

Fajasy on X

DigiPowerX $DGXX said on October 13 that it "did not issue any shares" under its ATM program in Q3. $DGXX's Q3 10-Q, filed November 13, shows 2.85M shares issued for cash in Q3 for $11.3M, and counts them among the 30.8M shares it sold through the ATM in the first nine months of 2026. The share count rose 46% this year, from 69.4M at the end of 2025 to 101.4M as of November 12. The 10-Q also shows three details the Q3 earnings release left out: 1) Prepayment: Cerebras $CBRS, the AI chipmaker that's the tenant at $DGXX's Columbiana data center campus in Alabama, paid a $12M upfront charge in Q3 for building Phase 1. The charge can be refunded, less what's been spent on finished construction, in some cases before Phase 1 starts, including if $DGXX misses the final delivery date. 2) Spending: $145.5M went into property, equipment, and equipment deposits in the first nine months, paid for with $170.8M of net share sales. 3) GPUs: Equipment deposits rose to $23.9M from $8.5M at the end of 2025, and the 10-Q mentions next-generation $NVDA Vera Rubin systems $DGXX has "committed to purchase," without an amount. $DGXX's Q3 revenue rose 85% q/q to $12.2M, but its $1.0M of net income leaned on $8.6M of gains on its crypto and warrants. Cash was $95.2M and bitcoin and ether were $24.5M as of September 30. $DGXX also expects to close a $200M loan syndicated by Goldman Sachs $GS in Q4 2026 to finish Columbiana, with an unsecured $DGXX guarantee until construction is done. Even with the cash, crypto, and loan, $DGXX is ~$30M short of its 2027 plan (~$350M of capex, mostly for ~10 MW of AI inference capacity and Columbiana's Phase 2) before any Q4 2026 spending. $DGXX expects customer deposits and prepayments to be a main source of funding, and it has already sold $174.7M of the $175M its ATM prospectus covers. At $2.28/share, $DGXX's market cap is ~$231M, an EV of ~$112M after its cash and crypto. If Phase 1 is ready on December 15 as planned, Cerebras starts paying in January 2027, and its $12M prepayment can no longer be refunded.

Investor Letters

All letters

Is Nebius Fucked?

Nebius’ Q3 beat relied on $325 million of one-off partnership fees as it raised 2027 CapEx to $40–45 billion and may need $6–11 billion of…

NBIS $32B
Daniel Romero 6 clicks

Qualcomm Custom ASICs?

Qualcomm’s Alphawave SerDes, CPU cores and HBC could support custom AI ASICs as hyperscalers build heterogeneous fleets beyond GPUs.

QCOM $185B
Chipstrat 4 clicks
PRYMY · short

Prysmian Spa

Prysmian (PRYMY) is presented as a short position.

PRYMY $36B
Value Investors Club 1 click

Short CNM

Core & Main faces a short thesis centered on the risks in its roll-up strategy.

CNM $8.4B
Shallow Dives 1 click

Nomad Foods - The Yield Machine

Nomad Foods combines leading European frozen-food brands with a high dividend yield, buybacks and decade-low valuation, while private-label…

NOMD $1.7B
D Invests

Publications we follow

Every publication on this site, hand-picked.

130 publications

Newsletters 110

YouTube 4

Blogs 15

Seeking Alpha 88 of 294

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

376 firms

Sectors

Ordered by how often our editor reaches for them.